Open AccessFDA Approval Summary: Rucaparib for the Treatment of Patients with Deleterious BRCA ‐Mutated Metastatic Castrate‐Resistant Prostate Cancer
Author(s) -
Anscher Mitchell S.,
Chang Elaine,
Gao Xin,
Gong Yutao,
Weinstock Chana,
Bloomquist Erik,
Adeniyi Oluseyi,
Charlab Rosane,
Zimmerman Sarah,
SerlemitsosDay Maritsa,
Ning Yang Min,
Mayrosh Ruth,
Fuller Barbara,
Trentacosti Ann Marie,
Gallagher Pamela,
Bijwaard Karen,
Philip Reena,
Ghosh Soma,
Fahnbulleh Frances,
Diggs Felicia,
Arora Shaily,
Goldberg Kirsten B.,
Tang Shenghui,
AmiriKordestani Laleh,
Pazdur Richard,
Ibrahim Amna,
Beaver Julia A.
Publication year - 2021
Publication title -
the oncologist
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.176
H-Index - 164
eISSN - 1549-490X
pISSN - 1083-7159
DOI - 10.1002/onco.13585
Subject(s) - medicine , prostate cancer , oncology , olaparib , brca mutation , taxane , parp inhibitor , cancer , adverse effect , clinical trial , clinical endpoint , ovarian cancer , breast cancer , poly adp ribose polymerase , biochemistry , chemistry , polymerase , gene
The U.S. Food and Drug Administration (FDA) granted accelerated approval to rucaparib in May 2020 for the treatment of adult patients with deleterious BRCA mutation (germline and/or somatic)‐associated metastatic castrate‐resistant prostate cancer (mCRPC) who have been treated with androgen receptor‐directed therapy and a taxane. This approval was based on data from the ongoing multicenter, open‐label single‐arm trial TRITON2. The primary endpoint, confirmed objective response rate, in the 62 patients who met the above criteria, was 44% (95% confidence interval [CI]: 31%–57%). The median duration of response was not estimable (95% CI: 6.4 to not estimable). Fifty‐six percent of patients had a response duration of >6 months and 15% >12 months. The safety profile of rucaparib was generally consistent with that of the class of poly‐(ADP‐ribose) polymerase enzyme inhibitors and other trials of rucaparib in the treatment of ovarian cancer. Deaths due to adverse events (AEs) occurred in 1.7% of patients, and 8% discontinued rucaparib because of an AE. Grade 3–4 AEs occurred in 59% of patients. No patients with prostate cancer developed myelodysplastic syndrome or acute myeloid leukemia. The trial TRITON3 in patients with mCRPC is ongoing and is planned to verify the clinical benefit of rucaparib in mCRPC. This article summarizes the FDA thought process and data supporting this accelerated approval. Implications for Practice The accelerated approval of rucaparib for the treatment of adult patients with deleterious BRCA mutation (germline and/or somatic)‐associated metastatic castrate‐resistant prostate cancer who have been treated with androgen receptor‐directed therapy and a taxane represents the first approved therapy for this selected patient population. This approval was based on a single‐arm trial demonstrating a confirmed objective response rate greater than that of available therapy with a favorable duration of response and an acceptable toxicity profile. The ongoing trial TRITON3 is verifying the clinical benefit of this drug.